CINQAIR® (reslizumab) Injection – About Asthma Control
Cinqair (Reslizumab) 100mg/10mL Injection – Apothera
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Teva Announces EMA Validation of Reslizumab Marketing Authorization Application
Llega reslizumab, terapia adicional reduce exacerbaciones asma grave
Reslizumab Overview - Creative Biolabs
Reslizumab | New Drug Approvals
Teva-Handok wins approval for anti-asthma injection < Pharma < Article - KBR
Israeli Pharma gets FDA Approval for Asthma Antibody
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
A program supporting CINQAIR® (reslizumab) Injection patients
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval
Reslizumab
Reslizumab (Sch 55700) | IL-5 Antagonist mAb | MedChemExpress
761033Orig1s000
FDA approves Teva's Cinqair (reslizumab) Injection
NICE changes mind and backs new drug for severe asthma | Nursing Times
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
Teva files MAA for asthma treatment reslizumab
Reslizumab - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
Teva Reports Two Successful Phase III Studies For Reslizumab In Asthma
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Dosing and Administration
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Reslizumab | New Drug Approvals
Teva's Severe Asthma Therapy Reslizumab Now Approved in Europe | RT
NICE Recommends CINQAERO (reslizumab) for the Treatment of Severe Eosinophilic Asthma » FINCHANNEL
